Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Feb 2;29(2):816-833.
doi: 10.3390/curroncol29020069.

Micro-RNAs, the Cornerstones of the Future of Radiobiology in Head and Neck Cancers?

Affiliations
Review

Micro-RNAs, the Cornerstones of the Future of Radiobiology in Head and Neck Cancers?

Camil Ciprian Mireștean et al. Curr Oncol. .

Abstract

Even though it is only the 6th most common malignancy at the modal level, head and neck cancers are distinguished by a considerable treatment failure rate, especially by locoregional recurrences, the intrinsic tumor radioresistance being one of the causes of this phenomenon. The efforts of radiobiological research of these cancers are oriented towards the identification of biomarkers associated with radioresistance and radiosensitivity in order to modulate the treatment so that the therapeutic benefit is maximum. Micro-RNAs (miRNAs, miRs), small single-stranded non-coding RNA molecules are currently being extensively evaluated as potential biomarkers in numerous diseases, including cancer. The evaluation of the potential of miRNAs to modulate or predict radiosensitivity or radioresistance, to anticipate the risk of recurrence and metastasis, and to differentiate different tumor subtypes is based on multiple mechanisms by which mRNAs control proliferation and apoptosis and interact with cell cycle phases or act as oncogenes with the potential to influence invasion promotion or tumor suppression. A refinement of radiosensitivity based on miRNAs with clinical and radiobiological application in head and neck cancers can lead to a personalization of radiotherapy. Thus, a miRNA signature can anticipate the risk of toxicity associated with chemoradiation, the possibility of obtaining locoregional control after treatment, and the recurrence and distant metastasis risk. The potential of miRNAs as an intrinsic predictor of sensitivity to chemotherapy may also guide the therapeutic decision toward choosing an escalation or de-escalation of concurrent or sequential systemic treatment. The choice of the irradiated dose, the fractional dose, the fractionation scheme, and the refining of the dose-volume constraints depending on the radiosensitivity of each tissue type estimated on a case-by-case basis by miRNAs profile are possible concepts for the future radiotherapy and radiobiology of head and neck cancers.

Keywords: chemotherapy; head and neck cancers; microRNAs; radiobiology; radioresistance; radiosensitivity.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Similar articles

Cited by

References

    1. Epidemiology and Risk Factors for Head and Neck Cancer, Global Cancer Observatory International Agency for Research on Cancer. World Health Organization. [(accessed on 6 June 2021)]. Available online: https://gco.iarc.fr/
    1. Brockstein B., Haraf D.J., Rademaker A.W., Kies M.S., Stenson K.M., Rosen F., Mittal B.B., Pelzer H., Fung B.B., Witt M.E., et al. Patterns of failure, prognostic factors and survival in locoregionally advanced head and neck cancer treated with concomitant chemoradiotherapy: A 9-year, 337-patient, multi-institutional experience. Ann Oncol. 2004;15:1179–1186. doi: 10.1093/annonc/mdh308. - DOI - PubMed
    1. Vigneswaran N., Williams M.D. Epidemiologic trends in head and neck cancer and aids in diagnosis. Oral Maxillofac. Surg. Clin. N. Am. 2014;26:123–141. doi: 10.1016/j.coms.2014.01.001. - DOI - PMC - PubMed
    1. Chang J.H., Wu C.C., Yuan K.S., Wu A.T.H., Wu S.Y. Locoregionally recurrent head and neck squamous cell carcinoma: Incidence, survival, prognostic factors, and treatment outcomes. Oncotarget. 2017;8:55600–55612. doi: 10.18632/oncotarget.16340. - DOI - PMC - PubMed
    1. Langendijk J.A., Doornaert P., Verdonck-de Leeuw I.M., Leemans C.R., Aaronson N.K., Slotman B.J. Impact of late treatment-related toxicity on quality of life among patients with head and neck cancer treated with radiotherapy. J. Clin. Oncol. 2008;26:3770–3776. doi: 10.1200/JCO.2007.14.6647. - DOI - PubMed